Agenus Inc. ("Agenus") , a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona ...
CureVac N.V. ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical ...
Open Polytechnic, a business division of Te Pūkenga, and New Zealand’s specialist provider of online and distance learning, recently published its annual Research Report for 2023.
AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY) September 17, 2024 - Investorideas , a go-to investing platform, releases the first of a two-part series looking at news and developments for the ...
People can be protected and the spread of mpox stopped if health organizations, countries and wider stakeholders work in solidarity, with equity at the heart of the response. We recognize the ...
The result saw worries over potential toxicity slow research ... Roche’s Kadcyla (trastuzumab emtansine), and Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan).
A New AI-based study enrolls first patient, strengths and weakness in multiple myeloma treatment are examined, and tafasitamab combination scores in FL. Fam-trastuzumab deruxtecan-nxki ... This ...
Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.
reinforce earlier findings of the benefits of the drug – trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate – in these patients, trial leaders say. The results of the trial, dubbed the DESTINY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback